Cross-Sector entity
Of the tracked stories, 5 of 5 also mention GSK, the most common co-covered peer. Across a 160-day span, the pace is roughly 0.2 stories per week. The busiest single day carried 3. The clearest coverage concentration is market-trends: 2 of 5 stories, with the rest divided among 3 other categories.
5 verified stories tracked
Last mentioned: Aug 4, 2026
Entity pulse
Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.
Of the tracked stories, 5 of 5 also mention GSK, the most common co-covered peer. Across a 160-day span, the pace is roughly 0.2 stories per week. The busiest single day carried 3. The clearest coverage concentration is market-trends: 2 of 5 stories, with the rest divided among 3 other categories. Each carries 2 original sources on average. This profile follows 5 Cross-Sector stories mentioning Wave Life Sciences across the period from February 26, 2026 to August 4, 2026. Negative sentiment appears in 0% of the tracked stories.
Computed from the 5 stories linked to this entity. Beat comparisons are omitted because no baseline was available for this window.
Coverage cohort
Other entities that clear the same relevance threshold in stories also covering Wave Life Sciences. Shared-story counts are live from our verified record — not editorial picks.
FY 2025 Earnings
Wave and Collegium release full-year financial results and 2026 guidance.
Anticipated Filing
Expected regulatory submission for WVE-N531 in Duchenne muscular dystrophy.
RNA Editing Milestone
WVE-006 demonstrates successful RNA editing in AATD patients.
DMD Breakthrough
Wave reports industry-leading dystrophin expression for WVE-N531.
Wave Life Sciences presented Phase I data for WVE-007, an siRNA targeting Activin E, demonstrating up to 88% serum reduction sustained for over 7.5 months. The INLIGHT Phase IIa trial is now enrolling 160 patients across four cohorts, with a focus on BMI 35–50 and type 2 diabetes status, aiming to validate the RNA editing platform's potential for durable obesity treatment.
Wave Life Sciences' WVE-007, a novel siRNA silencing Activin E, demonstrated a 16.5% improvement in visceral fat-to-muscle ratio in Phase I, outpacing existing therapies and offering a potential solution for the 70% of GLP-1 users who discontinue within a year. With enrollment underway in the INLIGHT Phase IIa trial, the 175 million individuals with obesity in the U.S. and Europe may soon have a longer-lasting, disease-modifying option.
Source: Motley Fool Transcribing (us) · fool.com
Wave Life Sciences and Collegium Pharmaceutical released their full-year 2025 financial results, highlighting a pivotal year for RNA therapeutics and specialty pain management. While Wave focuses on clinical milestones for its RNA editing platform, Collegium is driving growth through its commercial ADHD and pain portfolios.
Wave Life Sciences and Collegium Pharmaceutical reported full-year 2025 results, highlighting a transformative period for RNA editing and commercial pain management. Wave's clinical progress in AATD and DMD remains a primary valuation driver, while Collegium continues to optimize its specialized portfolio through strategic acquisitions.
Wave Life Sciences and Collegium Pharmaceutical released their Q4 and full-year 2025 results, highlighting a pivotal year for RNA editing and specialty pain management. Wave's transition toward a commercial-stage biotech is accelerated by its GSK partnership and landmark clinical data in Alpha-1 antitrypsin deficiency.
Source: manilatimes.net · manilatimes.net
